Three different combinations of BRAF/MEK inhibitors (BRAF/MEKi) have been shown to be effective and are approved for use in patients with BRAF mutated melanoma.2, 3, 4 On the other hand, immune checkpoint inhibitors (ICI) are FDA‐approved and effective for patients whose melanoma harbors a BRAF mutation. The gene discussed is MAP2K7; the disease is melanoma.